Peer-reviewed article
Efficacy and Safety of Tiotropium in Children and Adolescents
Eckard H. Hamelmann, Stanley James Szefler ·
Summary
Written by AI, not yet AICS's view · claude-haiku-4-5-20251001This review examines tiotropium, a long-acting bronchodilator, as a treatment for children and adolescents with moderate to severe asthma. Clinical trials show that tiotropium delivered via inhaler is well-tolerated and improves lung function when added to existing asthma medications. The review highlights challenges in managing asthma in young patients, including poor medication adherence, underreporting of symptoms, and psychological factors that affect treatment success.
Key points
- Tiotropium Respimat is approved for maintenance therapy in children over 6 years old with asthma
- Trials demonstrate tiotropium is well-tolerated and efficacious as add-on therapy to inhaled corticosteroids
- Treatment showed improved lung function and trends towards improved asthma control in children and adolescents
- Poor adherence, symptom underreporting, and social-psychological issues complicate asthma management in this age group
- Active review and management of treatment is needed to achieve optimal asthma control
Limitations
This is a narrative review synthesizing existing clinical trial evidence rather than presenting new primary research data. The document does not provide detailed information about study sample sizes, specific outcome measures, or comparative effectiveness against other treatment approaches.
Abstract
Asthma is one of the most common chronic diseases in children, with a high proportion of patients demonstrating poor control despite the availability of disease management guidelines. Global Initiative for Asthma guidelines include tiotropium as an add-on therapy option at Steps 4 and 5 in patients aged ≥ 12 years with a history of exacerbations, and tiotropium delivered via the Respimat ® Soft Mist™ Inhaler has recently been approved for use as once-daily maintenance therapy for children with asthma over the age of 6 years in the USA. A large clinical trial program has been conducted in children, adolescents, and adults across the spectrum of asthma severity. Findings from these clinical studies and pooled analyses in children and adolescents with symptomatic moderate or severe asthma have demonstrated that tiotropium Respimat ® as add-on to inhaled corticosteroids, with or without other maintenance therapies, is a well-tolerated and efficacious bronchodilator, showing improved lung function and trends towards improved asthma control, mirroring findings in adult studies. This review discusses the evidence to date for tiotropium Respimat ® for the management of asthma in adolescents and children with symptomatic moderate and severe asthma, and considers the challenges of asthma management in these patients. Factors affecting this population group, such as poor adherence, underreporting of symptoms, and social and psychological issues, are highlighted, along with the need for active review and management of treatment to help achieve optimal control.
Findings the Hub has extracted
Each claim below is labelled by its type of design and links back to this report.
Problem
Poor asthma control in children and adolescents despite available disease management guidelines
- Intervention
- Tiotropium Respimat add-on therapy to inhaled corticosteroids, with or without other maintenance therapies
- Population
- Children and adolescents over 6 years old with symptomatic moderate or severe asthma
Key finding
Tiotropium Respimat demonstrated improved lung function in children and adolescents